AstraZeneca Crestor Vs. Lipitor Study Shows Advantage In LDL, HDL Effect
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Phase III results from a trial comparing AstraZeneca’s investigational HMG-CoA reductase inhibitor Crestor to Pfizer’s Lipitor demonstrated statistically significant superiority for Crestor in reducing levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apo B), as well as in raising levels of high-density lipoprotein cholesterol (HDL-C), according to an abstract.